DE-BIOCORP
1.10.2020 07:32:15 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS® ), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
Belkin præsenterer nye løsninger til at strømforsyne, lokalisere og personalisere hverdagens teknologi3.9.2026 10:00:00 CEST | Pressemeddelelse
Belkin International kan findes på IFA-messen i udstillingshal 3.2, stand nr. 117 Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag en ny kollektion af tilsluttet tilbehør, enhedsbeskyttelse og livsstilsløsninger, der er designet til at hjælpe forbrugerne med at holde styr på og personalisere de enheder, de er afhængige af. Den nye portefølje omfatter SureFind-kollektionen, BoostCharge Slim Magnetic Ring Stand, UltraCharge Smart Display-powerbanks og nye farvevarianter af Belkins populære BoostCharge Compact USB-C-oplader 30 W. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903932800/da/ Product lineup showcasing Belkin's newest mobile power accessories De nye produkter bygger på idéen om, at teknologi skal passe problemfrit ind i en moderne l
Quectel Expands RG660Qx 5G Module Capabilities for Future Railway Mobile Communication System Evaluation and Railway Applications3.9.2026 10:00:00 CEST | Press release
High-performance Sub-6GHz 5G module platform with support for FRMCS-related frequency bands enables early evaluation through a dedicated development environment. Quectel Wireless Solutions, a global IoT solutions provider, today announced an LGA version of its RG660Qx 5G module series, a high performance, Sub-6GHz 5G module platform that includes support for the Future Railway Mobile Communication System (FRMCS). Used with a dedicated evaluation environment comprising an adaptor board and EVB Kit, the RG660Qx enables equipment manufacturers and railway technology developers to conduct early Future Railway Mobile Communication System (FRMCS) evaluation and testing, supporting development ahead of the transition from GSM-R. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903961434/en/ Quectel expands RG660Qx 5G module capabilities for Future Railway Mobile Communication System evaluation and railway applications The Future R
Belkin introducerer fremtidens bærbare strømforsyning med nye UltraCharge Pro Power Banks med halvfaste celler3.9.2026 10:00:00 CEST | Pressemeddelelse
Den næste generation af bærbar strømforsyning præsenteres for første gang på IFA 2026 og fremviser avanceret BoostSolid Cell-teknologi og ultraslanke design Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag nye bærbare opladningsløsninger baseret på halvfast celleteknologi. Den nye UltraCharge Pro med BoostSolid Cell-serie er blandt Belkins første produkter med halvfast celleteknologi, et batteri af næste generation, der leverer forbedret holdbarhed, slankt design og længere batteritid – alt sammen uden at gå på kompromis med ydeevnen. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903417354/da/ Product image showcasing the first two Belkin power banks launched with BoostSolid technology Batteriteknologi af næste generation til længerevarende
I’m green™ bio-based Helps Deterra® Win Multiple Industry Awards for Pharmaceutical Packaging3.9.2026 10:00:00 CEST | Press release
The Deterra® Drug Disposal Pouch, which is made with 50% or more I'm green™ bio-based polymer, has gained Accredo Packaging a number of leading packing industry awards. Developed by Verde, the patented drug disposal technology is designed to deactivate unused medications, preventing drug diversion and mitigating the risk of pharmaceuticals leaching into groundwater and waterways. The partial use of I’m green™ bio-based polymer derived from renewable sugarcane, reduces the carbon footprint of the packaging material compared to equivalent fossil-based polyethylene, all whilst maintaining the technical performance required for pharmaceutical disposal applications. Material Innovation and Application The Deterra® pouch required a material that could meet strict technical specifications without relying entirely on traditional, fossil-based plastics. By utilizing I’m green™ bio‑based polyethylene, the packaging has a reduced carbon footprint whilst maintaining the performance of conventional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom